Nepicastat (free base) reduced cortical NE levels in Dbh +/− mice compared with saline vehicle. In DAT-KO mice, treatment reduced PFC tissue NE levels and elevated DA levels without altering 5-HT levels. In LLC-implanted mice exposed to CIH, treatment significantly inhibited CIH-induced tumor growth and decreased CIH-induced serum NE and EPI levels compared with CIH plus vehicle. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Nepicastat reduces cortical NE in Dbh +/− mice
Animal study · Dbh +/− mice [1]
Dbh +/− mice received nepicastat by i.p. injection. Cortical NE levels were reduced compared with saline vehicle.
Conditions shared by the study groups
- Route
- i.p.
- Treatment course
- 3 times, each injection two hours apart
- Vehicle
- sterile saline
- Nepicastat (free base) 50 mg/kg
- Model: Dbh +/− mice
Methods and source locations
Compound reported in the paper: Nepicastat (free base); Compound label in the paper: Nepicastat
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods > Drugs (S15); Materials and Methods > Quantification of Norepinephrine Levels (S22); Results > Nepicastat Reduces Brain NE content in Dbh +/− Mice (S57, S58)
cortical NE levels: cortical NE levels; comparator: saline (10 ml/kg, i.p.) — Materials and Methods > Quantification of Norepinephrine Levels (S22); Results > Nepicastat Reduces Brain NE content in Dbh +/− Mice (S58)
Nepicastat (free base) 50 mg/kg · Materials and Methods > Quantification of Norepinephrine Levels (S22); Results > Nepicastat Reduces Brain NE content in Dbh +/− Mice (S58)
Nepicastat and CIH-Induced Tumor Growth in LLC-Implanted Mice
Animal study · 6-week-old male C57BL/6 N mice; LLC-implanted mice; n = 12 in each group [2]
In LLC-implanted mice exposed to CIH, Nepicastat (free base) administered by oral gavage significantly inhibited CIH-induced tumor growth compared with CIH plus vehicle.
Conditions shared by the study groups
- Route
- oral gavage
- Treatment course
- Prior to daily exposure; 4 weeks
- Vehicle
- carboxymethylcellulose sodium (CMC-Na, Sangon Biotech)
- Nepicastat (free base) 10 mg/kg body weight
- Model: 6-week-old male C57BL/6 N mice; LLC-implanted mice; n = 12 in each group
Methods and source locations
Compound reported in the paper: Nepicastat (free base); Compound label in the paper: Nepicastat
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Methods > Animals and chronic intermittent hypoxia exposure (S8, S12, S16, S19, S20, S22, S23); Methods > Serum and tissue sample preparation from LLC-implanted mice (S28); Results > The suppression of catecholamine-βAR effectively inhibits CIH-induced murine lung cancer progression (S68)
Tumor volume: Tumor volume; comparator: CIH plus vehicle (CIH + Vehi) — Methods > Animals and chronic intermittent hypoxia exposure (S22); Results > The suppression of catecholamine-βAR effectively inhibits CIH-induced murine lung cancer progression (S68)
Nepicastat (free base) 10 mg/kg body weight · Methods > Animals and chronic intermittent hypoxia exposure (S19, S23); Results > The suppression of catecholamine-βAR effectively inhibits CIH-induced murine lung cancer progression (S68)
Nepicastat alters PFC catecholamine levels in DAT-KO mice
Animal study · DAT-KO mice [3]
HPLC analysis of PFC tissue from DAT-KO mice systemically injected with nepicastat showed reduced tissue NE levels and elevated tissue DA levels without altering 5-HT levels.
Conditions shared by the study groups
- Route
- i.p. injection
- Vehicle
- 1% DMSO and 10% hydroxypropyl-cyclodextrin (Sigma) and brought up to volume with saline
- Nepicastat (free base) 40 mg/kg
- Model: DAT-KO mice
- Reported limits: Not stated in the sentences used: schedule.
Methods and source locations
Compound reported in the paper: Nepicastat (free base); Compound label in the paper: Nepicastat
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results (S50, S51, S58, S59); Methods > Animals and drugs (S66)
NE, DA or 5-HT levels by HPLC: NE, DA or 5-HT levels by HPLC; comparator: vehicle (veh) treated — Results (S50, S51, S58)
Nepicastat (free base) 40 mg/kg · Results (S50, S51, S58)
Nepicastat and Serum NE and EPI in CIH-Exposed Mice
Animal study · 6-week-old male C57BL/6 N mice; LLC-implanted mice; n = 12 in each group [2]
In LLC-implanted mice exposed to CIH, Nepicastat (free base) administered by oral gavage decreased CIH-induced serum NE and EPI levels compared with CIH plus vehicle.
Conditions shared by the study groups
- Route
- oral gavage
- Treatment course
- Prior to daily exposure; 4 weeks
- Vehicle
- carboxymethylcellulose sodium (CMC-Na, Sangon Biotech)
- Nepicastat (free base) 10 mg/kg body weight
- Model: 6-week-old male C57BL/6 N mice; LLC-implanted mice; n = 12 in each group
Methods and source locations
Compound reported in the paper: Nepicastat (free base); Compound label in the paper: Nepicastat
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Methods > Animals and chronic intermittent hypoxia exposure (S8, S12, S16, S19, S20, S23); Methods > Serum and tissue sample preparation from LLC-implanted mice (S28); Results > The suppression of catecholamine-βAR effectively inhibits CIH-induced murine lung cancer progression (S70, S71, S83)
ELISA results of NE and EPI in mouse serum: ELISA results of NE and EPI in mouse serum; comparator: CIH plus vehicle (CIH + Vehi) — Results > The suppression of catecholamine-βAR effectively inhibits CIH-induced murine lung cancer progression (S71, S83)
Nepicastat (free base) 10 mg/kg body weight · Methods > Animals and chronic intermittent hypoxia exposure (S19, S23); Results > The suppression of catecholamine-βAR effectively inhibits CIH-induced murine lung cancer progression (S71)